NEW ORLEANS, American Academy of Ophthalmology, Oct 22, 2004 /PRNewswire via COMTEX/ -- Biosyntrx, (www.biosyntrx.com) a research-based ophthalmic company providing nutraceutical products that support optimal eye and body health today announced the launch of Oculair, its whole body product to replace Syntrx Complete, and formulated to reflect recent peer-review nutrition science.
Oculair is a full-spectrum multiple vitamin, mineral, antioxidant formulation designed to protect the entire body, including the eyes from damaging effects of free radicals, which are responsible for the progression of all chronic degenerative diseases.
Oculair provides all of the nutrients included in the ARED study, plus efficacious amounts of full-spectrum B vitamins which are required to keep homocysteine levels in check -- an important issue for the dry AMD patient. Recent science suggests a higher and earlier incidence of wet AMD in those patients with elevated homocysteine levels. Oculair is also safe for long-term consumption as well as for patients who are smokers or have a smoking history.
"Consumers are become increasingly cost conscious about their health needs in the wake of escalating prescription drug prices, and their physicians are paying attention," said Spencer Thornton, MD, President and CEO of Biosyntrx. "To equal the active micronutrients in just 4 Oculair capsules, consumers would need to take up to 40 capsules of separate nutrients a day and spend more than $150.00 per month. At less than a quarter of this amount, Oculair represents a more complete product and a very good value."
"I'm recommending Oculair to my patients for macular protection as well as whole body support," said Marguerite McDonald, MD, of New Orleans, Past President of the American Society of Cataract and Refractive Surgery.
While Oculair includes all the minerals and antioxidants in the original Syntrx Complete formulation, as well as those used in the AREDs and Lutein Antioxidant Supplement Trial (LAST), it is far more complete and provides better absorption than either formula.
Specifically, Oculair reflects changes in the LAST lutein/zeaxanthin ratio based on the most recent science, which strongly suggests a central macula preference for zeaxanthin. Oculair includes 7 mg of FloraGlo lutein, 3 mg of zeaxanthin from Roche and 1 mg of lycopene.
"Biosyntrx is excited about Oculair, which is by far the most complete formulation available to the AMD patient, and the best entry-level nutraceutical for younger patients without AMD who want to boost antioxidant levels at affordable prices," said Dr. Thornton. "Thought leading ophthalmologists and optometrists will want to recommend Oculair to their entire patient base."
Biosyntrx' Macula Complete(TM) is a more appropriate formulation for the diagnosed AMD patient at a higher price point because it includes more acetyl-l-carnitine, lipoic acid, and CoQ10, which are all important mitochondria "housekeepers".
Biosyntrx, founded in 2002, is a privately held, research-based ophthalmic company based in Lexington, South Carolina. It develops and markets nutraceutical products that support optimal eye and body health: Oculair (TM), containing optimal amounts of nutrients to help protect the eyes and body from the damaging effects of free radicals and the aging process; Macula Complete, a more potent multiple for the diagnosed AMD patient that also includes efficacious amounts of acetyl-l-carnitine, CoQ10 and lipoic acid, as well as "BioTears Oral GelCaps(TM), the most complete formulation addressing the complex inflammatory issues of age-related and surgically induced dry eye syndrome.
Biosyntrx is committed to proving the science that supports each formulation with cohort studies designed around ophthalmic clinical markers. For further information please visit www.biosyntrx.com or call Joe Kirkland, COO at 800-688-6815.